Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can theoretically be converted into any somatic cell type. hESCs and hiPSCs carrying genetic defects can now be produced to model diseases in vitro. We suggest several guiding principles to help ensure an optimal fit between technology and disease.